Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances
The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1354313/full |
| _version_ | 1797307024321544192 |
|---|---|
| author | Xiang Wang Zijun Yuan Zhengbo Li Xinyu He Yinping Zhang Xingyue Wang Jiahong Su Xu Wu Xu Wu Xu Wu Mingxing Li Mingxing Li Mingxing Li Fukuan Du Fukuan Du Fukuan Du Yu Chen Yu Chen Yu Chen Shuai Deng Shuai Deng Shuai Deng Yueshui Zhao Yueshui Zhao Yueshui Zhao Jing Shen Jing Shen Jing Shen Tao Yi Zhangang Xiao Zhangang Xiao Zhangang Xiao |
| author_facet | Xiang Wang Zijun Yuan Zhengbo Li Xinyu He Yinping Zhang Xingyue Wang Jiahong Su Xu Wu Xu Wu Xu Wu Mingxing Li Mingxing Li Mingxing Li Fukuan Du Fukuan Du Fukuan Du Yu Chen Yu Chen Yu Chen Shuai Deng Shuai Deng Shuai Deng Yueshui Zhao Yueshui Zhao Yueshui Zhao Jing Shen Jing Shen Jing Shen Tao Yi Zhangang Xiao Zhangang Xiao Zhangang Xiao |
| author_sort | Xiang Wang |
| collection | DOAJ |
| description | The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors. |
| first_indexed | 2024-03-08T00:51:21Z |
| format | Article |
| id | doaj.art-c80dd779a6ee4d84a1bde245d4362c20 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T00:51:21Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c80dd779a6ee4d84a1bde245d4362c202024-02-15T04:35:30ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13543131354313Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advancesXiang Wang0Zijun Yuan1Zhengbo Li2Xinyu He3Yinping Zhang4Xingyue Wang5Jiahong Su6Xu Wu7Xu Wu8Xu Wu9Mingxing Li10Mingxing Li11Mingxing Li12Fukuan Du13Fukuan Du14Fukuan Du15Yu Chen16Yu Chen17Yu Chen18Shuai Deng19Shuai Deng20Shuai Deng21Yueshui Zhao22Yueshui Zhao23Yueshui Zhao24Jing Shen25Jing Shen26Jing Shen27Tao Yi28Zhangang Xiao29Zhangang Xiao30Zhangang Xiao31Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaDepartment of Laboratory Medicine, The Longmatan District People’s Hospital, Luzhou, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaCell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, ChinaSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaCell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, ChinaSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaCell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, ChinaSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaCell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, ChinaSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaCell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, ChinaSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaCell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, ChinaSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaCell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, ChinaSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan, ChinaSchool of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong SAR, ChinaLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, ChinaCell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, ChinaSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan, ChinaThe incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1354313/fulltumor-infiltrating lymphocytes (TILs)hepatocellular carcinoma (HCC)immunotherapysignaling pathwayTILs preparationtargeting neoantigens |
| spellingShingle | Xiang Wang Zijun Yuan Zhengbo Li Xinyu He Yinping Zhang Xingyue Wang Jiahong Su Xu Wu Xu Wu Xu Wu Mingxing Li Mingxing Li Mingxing Li Fukuan Du Fukuan Du Fukuan Du Yu Chen Yu Chen Yu Chen Shuai Deng Shuai Deng Shuai Deng Yueshui Zhao Yueshui Zhao Yueshui Zhao Jing Shen Jing Shen Jing Shen Tao Yi Zhangang Xiao Zhangang Xiao Zhangang Xiao Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances Frontiers in Immunology tumor-infiltrating lymphocytes (TILs) hepatocellular carcinoma (HCC) immunotherapy signaling pathway TILs preparation targeting neoantigens |
| title | Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances |
| title_full | Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances |
| title_fullStr | Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances |
| title_full_unstemmed | Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances |
| title_short | Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances |
| title_sort | key oncogenic signaling pathways affecting tumor infiltrating lymphocytes infiltration in hepatocellular carcinoma basic principles and recent advances |
| topic | tumor-infiltrating lymphocytes (TILs) hepatocellular carcinoma (HCC) immunotherapy signaling pathway TILs preparation targeting neoantigens |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1354313/full |
| work_keys_str_mv | AT xiangwang keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT zijunyuan keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT zhengboli keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT xinyuhe keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT yinpingzhang keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT xingyuewang keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT jiahongsu keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT xuwu keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT xuwu keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT xuwu keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT mingxingli keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT mingxingli keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT mingxingli keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT fukuandu keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT fukuandu keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT fukuandu keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT yuchen keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT yuchen keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT yuchen keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT shuaideng keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT shuaideng keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT shuaideng keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT yueshuizhao keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT yueshuizhao keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT yueshuizhao keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT jingshen keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT jingshen keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT jingshen keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT taoyi keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT zhangangxiao keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT zhangangxiao keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances AT zhangangxiao keyoncogenicsignalingpathwaysaffectingtumorinfiltratinglymphocytesinfiltrationinhepatocellularcarcinomabasicprinciplesandrecentadvances |